Literature DB >> 23359767

Glycogen Synthase Kinase 3β Inhibitor (2'Z,3'E)-6-Bromo-indirubin- 3'-Oxime Enhances Drug Resistance to 5-Fluorouracil Chemotherapy in Colon Cancer Cells.

Kun-Ping Liu1, Feng Luo, Si-Ming Xie, Li-Juan Tang, Mei-Xiang Chen, Xue-Fang Wu, Xue-Yun Zhong, Tong Zhao.   

Abstract

OBJECTIVE: To explore the effects and mechanism of glycogen synthase kinase 3β (GSK-3β) inhibitor (2'Z,3'E)-6-bromo-indirubin-3'-oxime (BIO) on drug resistance in colon cancer cells.
METHODS: The colon cancer SW480 and SW620 cells were treated with BIO, 5-fluorouracil (5-FU) and BIO/5-FU, separately. Cell cycle distribution, apoptosis level and efflux ability of rhodamine 123 (Rh123) were detected by flow cytometry. The protein expressions of P-glycoprotein (P-gp), multidrug resistance protein 2 (MRP2), thymidylate synthase (TS), β-catenin, E2F-1 and Bcl-2 were detected by Western blot. β-catenin and P-gp were stained with double immunofluorescence and observed under a confocal microscope.
RESULTS: BIO up-regulated β-catenin, P-gp, MRP2 and TS, enhanced the efflux ability of Rh123, decreased Bcl-2 protein and gave the opposite effect to E2F-1 protein in SW480 and SW620 cells. Furthermore, BIO significantly inhibited cell apoptosis, increased S and G(2)/M phase cells, and reduced the cell apoptosis induced by 5-FU in SW480 cells, whereas the effects were slight or not obvious in SW620 cells.
CONCLUSION: GSK-3β was involved in drug resistance regulation, and activation of β-catenin and inhibition of E2F-1 may be the most responsible for the enhancement of 5-FU chemotherapy resistance induced by GSK-3β inhibitor BIO in colon cancer.

Entities:  

Keywords:  Colorectal neoplasms; Drug resistance; E2F-1; Fluorouracil; Glycogen synthase kinase 3β; β-catenin

Year:  2012        PMID: 23359767      PMCID: PMC3555271          DOI: 10.1007/s11670-012-0116-9

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  47 in total

1.  Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance.

Authors:  Pornsiri Pitchakarn; Shinobu Ohnuma; Komsak Pintha; Wilart Pompimon; Suresh V Ambudkar; Pornngarm Limtrakul
Journal:  J Nutr Biochem       Date:  2011-03-16       Impact factor: 6.048

2.  Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation.

Authors:  Abbas Shakoori; Andrei Ougolkov; Zhi Wei Yu; Bin Zhang; Mohammad H Modarressi; Daniel D Billadeau; Masayoshi Mai; Yutaka Takahashi; Toshinari Minamoto
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

3.  Glycogen synthase kinase-3beta binds to E2F1 and regulates its transcriptional activity.

Authors:  Gisela García-Alvarez; Verònica Ventura; Oriol Ros; Rosa Aligué; Joan Gil; Albert Tauler
Journal:  Biochim Biophys Acta       Date:  2006-09-15

4.  The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes.

Authors:  Ai-Sun Tseng; Felix B Engel; Mark T Keating
Journal:  Chem Biol       Date:  2006-09

5.  P-glycoprotein expression induced by glucose depletion enhanced the chemosensitivity in human hepatocellular carcinoma cell-lines.

Authors:  Samuel Chak-Sum Cheng; Jing Zhou; Yong Xie
Journal:  Cell Biol Int       Date:  2005-04       Impact factor: 3.612

6.  Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells.

Authors:  Andrei V Ougolkov; Nancy D Bone; Martin E Fernandez-Zapico; Neil E Kay; Daniel D Billadeau
Journal:  Blood       Date:  2007-04-26       Impact factor: 22.113

Review 7.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

8.  Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells.

Authors:  M Yeste-Velasco; J Folch; R Trullàs; M A Abad; M Enguita; M Pallàs; A Camins
Journal:  Neuropharmacology       Date:  2007-05-26       Impact factor: 5.250

9.  Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer.

Authors:  Aijing Sun; Ilanchezian Shanmugam; Jiawu Song; Paul F Terranova; J Brantley Thrasher; Benyi Li
Journal:  Prostate       Date:  2007-06-15       Impact factor: 4.104

Review 10.  Glycogen synthase kinase 3: a key regulator of cellular fate.

Authors:  J E Forde; T C Dale
Journal:  Cell Mol Life Sci       Date:  2007-08       Impact factor: 9.261

View more
  3 in total

1.  RNA binding protein RBM3 increases β-catenin signaling to increase stem cell characteristics in colorectal cancer cells.

Authors:  Anand Venugopal; Dharmalingam Subramaniam; Julia Balmaceda; Badal Roy; Dan A Dixon; Shahid Umar; Scott J Weir; Shrikant Anant
Journal:  Mol Carcinog       Date:  2015-08-31       Impact factor: 4.784

2.  Comparative profiling between primary colorectal carcinomas and metastases identifies heterogeneity on drug resistance.

Authors:  Feng Luo; Jinbang Li; Shigang Wu; Xuefang Wu; Meixiang Chen; Xueyun Zhong; Kunping Liu
Journal:  Oncotarget       Date:  2016-09-27

Review 3.  An Update on the Potential Roles of E2F Family Members in Colorectal Cancer.

Authors:  ZhaoHui Xu; Hui Qu; YanYing Ren; ZeZhong Gong; Hyok Ju Ri; Xin Chen
Journal:  Cancer Manag Res       Date:  2021-07-09       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.